Possible role of GPX1 polymorphism in modifying the response to anticancer therapy has already been suggested by Zhao et al. These authors conducted a prospective study on 224 patients with bladder cancer and observed that individuals possessing Pro/Pro genotype had shorter recurrence–free survival as compared to those with at least one variant (Leu) allele [37]. The gene discussed is GPX1; the disease is urinary bladder carcinoma.